FN2 Earnings Intelligence

Royalty Pharma plc earnings overview

Latest Royalty Pharma plc (RPRX) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.

Next reportRoyalty Pharma plc reports Wednesday, Nov 4, 2026 · Before market openConsensus EPS $1.18 · consensus revenue $884.8M
RPRX FY2026 Q3 · Calendar Q4 2026

Royalty Pharma plc

The Q3 call offers evidence of expanding royalty receipts and deal activity, alongside another full-year guidance increase. Those are supportive indicators, but they do not by themselves establish that growth will persist: execution depends on acquired assets, clinical outcomes and disciplined capital deployment.

EPS surprise—
Market move+1.4%

Get the RPRX recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.